NI 007 is an mRNA-encoded, neutralising anti-SARS-CoV-2 monoclonal antibody, being jointly developed by Neurimmune and Ethris, by using Neurimmune's Reverse Translational Medicine (RTMTM) technology platform, for the treatment of COVID-19 infections. Neutralising antibodies will be translated into therapeutic SNIM®RNA products for inhalation. Early research of an inhalation formulation, is underway in Switzerland.
Neurimmune's RTMTM technology focusses on the cloning of authentic human antibodies from healthy participants, or from patients who recovered from disease, by translating the immune memory of functionally active antibodies into transformative immunotherapeutics. With Ethris' proprietary pulmonary SNIM®RNA technology, the technology can express human SARS-CoV-2 neutralising antibodies directly in the lung to rapidly achieve effective pulmonary antibody concentrations.
In April 2020, Neurimmune entered into a research and development agreement with Ethris, to develop mRNA-encoded, neutralising anti-SARS-CoV-2 antibodies, administered by inhalation, for the treatment of COVID-19 infections. Under the terms of the agreement, Neurimmune and Ethris will jointly conduct research and development activities while sharing costs and revenues resulting from the collaboration. The companies intend to initiate manufacturing of the drug for planned clinical trials.